STOCKHOLDER AGREEMENTStockholder Agreement • September 14th, 2022 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS STOCKHOLDER AGREEMENT (this “Agreement”), dated as of September 12 2022, is made and entered into by and among Vickers Vantage Corp. I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, the “Company”), and Sorrento Therapeutics, Inc., a Delaware corporation (“Stockholder”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Merger Agreement (as defined below).
AMENDMENT NO.1 TO SPONSOR SUPPORT AGREEMENTSponsor Support Agreement • September 14th, 2022 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment to Sponsor Support Agreement (this “Amendment”), dated as of September 12, 2022 , is made and entered into by and among, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Jeffrey Chi, Chris Ho, Pei Wei Woo, Suneel Kaji, Steve Myint, Vickers Vantage Corp I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing), and Scilex Holding Company, a Delaware corporation.
AMENDMENT NO.1 TO AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • September 14th, 2022 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this “Amendment”), dated as of September 12, 2022, is made and entered into by and among Vickers Vantage Corp. I, a Cayman Islands exempted company (which shall migrate to and domesticate as a Delaware corporation prior to the Closing, “Parent”), Vantage Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Parent (the “Merger Sub” and together with Parent, collectively, the “Parent Parties”), and Scilex Holding Company, a Delaware corporation (the “Company”).
CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENTContribution and Satisfaction of Indebtedness Agreement • September 14th, 2022 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENT (this “Agreement”), entered into as of September 12, 2022 (the “Agreement Date”), is by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Sorrento”), SCILEX HOLDING COMPANY, a direct wholly owned subsidiary of Sorrento (“Scilex”), and SCILEX PHARMACEUTICALS, INC., an indirect wholly owned subsidiary of Sorrento and direct wholly owned subsidiary of Scilex (“Scilex Pharma”).
